Redirecting to https://www.gsk.com/en-gb/media/press-releases/jemperli-dostarlimab-approved-in-us-as-first-and-only-immunotherapy-for-adults-with-msi-hdmmr-locally-advanced-rectal-cancer/...

Click here if your browser doesn't automatically take you to this page.